Overview

A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant. The study is open to adults with type 1 or type 2 diabetes and will last about 50 days.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Locemia Solutions ULC
Treatments:
Glucagon